I did say 'towards' being cash positive in my defence. At this end of the mkt cap scale its often binary - a little partnership deal for a small to medium-sized pharma, but a massive boost to OSX could so easily appear. I have long said I consider many of my small bio-tech stocks holdings like this, call options in effect. One of my other small-cap bio-tech's, destined for a capital raise at year end, pulled a partnership out at fin year end that sets it up until 2028 arguably, but more likely forever unless management cock their other applications up.
OSX could so easily announce similar.
OSX Price at posting:
20.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)